BIO-TECHNE CORP (TECH) Stock Price, Quote, News and Overview
NASDAQ:TECH - Nasdaq - US09073M1045 - Common Stock - Currency: USD
TECH Quote, Performance and Key Statistics
64.15
-0.07 (-0.11%)
The current stock price of TECH is 64.15 USD. In the past month the price decreased by -14.01%. In the past year, price decreased by -13.75%.
TECH Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.4 | 203.98B | ||
| DHR | DANAHER CORP | 27.96 | 150.61B | ||
| A | AGILENT TECHNOLOGIES INC | 25.32 | 38.36B | ||
| IQV | IQVIA HOLDINGS INC | 17.14 | 33.63B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 31.33 | 26.98B | ||
| WAT | WATERS CORP | 32.43 | 22.86B | ||
| ICLR | ICON PLC | 14.01 | 16.20B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 32.55 | 15.91B | ||
| ILMN | ILLUMINA INC | 38.39 | 14.92B | ||
| RVTY | REVVITY INC | 23.49 | 14.01B | ||
| AVTR | AVANTOR INC | 17.22 | 11.73B | ||
| MEDP | MEDPACE HOLDINGS INC | 26.88 | 10.34B |
Related stock screener links
About TECH
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. The company is headquartered in Minneapolis, Minnesota and currently employs 3,100 full-time employees. The firm's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Company Info
BIO-TECHNE CORP
614 Mckinley Pl N E
Minneapolis MINNESOTA 55413 US
CEO: Charles Kummeth
Employees: 3100
Company Website: https://www.bio-techne.com/
Investor Relations: https://investors.bio-techne.com/
Phone: 16123798854
BIO-TECHNE CORP / TECH FAQ
What is the stock price of BIO-TECHNE CORP today?
The current stock price of TECH is 64.15 USD. The price decreased by -0.11% in the last trading session.
What is the ticker symbol for BIO-TECHNE CORP stock?
The exchange symbol of BIO-TECHNE CORP is TECH and it is listed on the Nasdaq exchange.
On which exchange is TECH stock listed?
TECH stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for BIO-TECHNE CORP stock?
22 analysts have analysed TECH and the average price target is 89.09 USD. This implies a price increase of 38.87% is expected in the next year compared to the current price of 64.15. Check the BIO-TECHNE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is BIO-TECHNE CORP worth?
BIO-TECHNE CORP (TECH) has a market capitalization of 10.14B USD. This makes TECH a Large Cap stock.
How many employees does BIO-TECHNE CORP have?
BIO-TECHNE CORP (TECH) currently has 3100 employees.
What are the support and resistance levels for BIO-TECHNE CORP (TECH) stock?
BIO-TECHNE CORP (TECH) has a support level at 64.14 and a resistance level at 70.66. Check the full technical report for a detailed analysis of TECH support and resistance levels.
Is BIO-TECHNE CORP (TECH) expected to grow?
The Revenue of BIO-TECHNE CORP (TECH) is expected to grow by 6.18% in the next year. Check the estimates tab for more information on the TECH EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy BIO-TECHNE CORP (TECH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TECH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TECH, evaluating the profitability, health, valuation and growth aspects
- BIO-TECHNE CORP (TECH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- BIO-TECHNE CORP (TECH) Sales and EPS estimates to see what analysts future expectations are.
- BIO-TECHNE CORP (TECH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- BIO-TECHNE CORP (TECH) Insider and Institutional Ownership to learn about the owners and their transactions.
- BIO-TECHNE CORP (TECH) Stock Chart to make your own analysis
- BIO-TECHNE CORP (TECH) Latest news and press-releases to stay up to date.
Does BIO-TECHNE CORP (TECH) stock pay dividends?
BIO-TECHNE CORP (TECH) has a dividend yield of 0.49%. The yearly dividend amount is currently 0.32. Check the full fundamental report for a detailed analysis of TECH dividend history, reliability and sustainability.
When does BIO-TECHNE CORP (TECH) report earnings?
BIO-TECHNE CORP (TECH) will report earnings on 2025-04-29, after the market close.
What is the Price/Earnings (PE) ratio of BIO-TECHNE CORP (TECH)?
The PE ratio for BIO-TECHNE CORP (TECH) is 35.44. This is based on the reported non-GAAP earnings per share of 1.81 and the current share price of 64.15 USD. Check the full fundamental report for a full analysis of the valuation metrics for TECH.
What is the Short Interest ratio of BIO-TECHNE CORP (TECH) stock?
The outstanding short interest for BIO-TECHNE CORP (TECH) is 2.52% of its float. Check the ownership tab for more information on the TECH short interest.
TECH Technical Analysis
TECH Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to TECH. TECH gets an excellent profitability rating and is at the same time showing great financial health properties.
TECH Financial Highlights
Over the last trailing twelve months TECH reported a non-GAAP Earnings per Share(EPS) of 1.81. The EPS decreased by -4.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.22% | ||
| ROA | 5.92% | ||
| ROE | 7.61% | ||
| Debt/Equity | 0.14 |
TECH Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to TECH. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 9.61% and a revenue growth 6.18% for TECH